PUK1 INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS)
May 1, 2010, 00:00
10.1016/S1098-3015(10)72356-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)72356-1/fulltext
Title :
PUK1 INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72356-1&doi=10.1016/S1098-3015(10)72356-1
First page :
Section Title :
Open access? :
No
Section Order :
959